Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients

Inclusion Criteria: * Age between 3 and 17 years, * IgE-mediated sesame allergy confirmed with positive skin prick tests with sesame allergens (diameter of the wheal greater than 3mm) and/or specific IgE level greater than 0.35-kilo units of Allergen per liter (kUA/l), * Allergic reaction to sesame protein during oral food challenge (OFC), * Signed Informed Consent by parent/legal guardian and patient aged \>16 years old, * Patient's and caregivers' cooperation with the researcher. Exclusion Criteria: * No confirmed sesame allergy, * Negative OFC with sesame protein (maximum dose 4000mg), * Severe asthma, uncontrolled mild/moderate asthma: forced expiratory volume at one second (FEV1)\<80% (under 5. percentile), FEV1/forced vital capacity (FVC)\<75% (under 5. percentile), hospitalization due to asthma exacerbation within last 12 months, * Current oral/sublingual/subcutaneous immunotherapy with other allergens in the first year of immunotherapy, * Eosinophilic gastroenteritis, * A history of severe recurrent anaphylaxis episodes, * Chronic diseases requiring continuous treatment, including heart disease, epilepsy, metabolic diseases, diabetes, * Medication: * oral, daily steroid therapy longer than 1 month within the last 12 months, * at least two courses of oral steroid therapy (at least 7 days) within the last 12 months, * oral steroid therapy longer than 7 days within the last 3 months, * any biological treatment, * therapy with β-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel inhibitors, * Pregnancy, * No consent to participate in the study, * Lack of patient or caregiver cooperation.